of the Alere INRatio®2 Prothrombin Time (PT) Monitoring System
Grace DeSantis, PhDLisa Croner, PhDMichealle Havenhill, BAShari Kipp, BSc (Honours) MBA
The product performance claims in this white paper are pending 510(k) clearance. The product available for sale has been cleared based on the performance claims in the
Prothrombin Time (PT) monitoring systems must demonstrate precision and accuracy, including comparability to standardized lab methods. This paper summarizes the performance of the Alere INRatio®2 PT/INR Monitoring System, consisting of a monitor and test strips with two levels of built-in quality control, across six test strip lots with over 350 duplicate INR measurements.
Precision was shown to be excellent across the entire therapeutic range (INR 2.0 to 4.5), with a mean INR of 3.0 and CV of 5.9%. Accuracy was also shown to be excellent with an overall correlation of 0.96 to the laboratory reference method.
INTRODUCTIONPatients on oral anticoagulation therapy (OAT) with warfarin require frequent monitoring using the prothrombin time (PT) test, reported in INR (International Normalized Ratio). The American College of Chest Physicians (ACCP) Consensus Guidelines recommends a therapeutic range between 2.0 to 3.0 INR.1 Individuals requiring more intensive therapy, such as with prosthetic (mechanical) heart valves in the mitral position, often have a target therapeutic range from 2.5 to 3.5 INR.
Everyone metabolizes warfarin differently.1 Too little warfarin results in underanticoagulation, increasing the risk of forming clots; too much warfarin results in overanticoagulation, increasing the risk of bleeding. Frequent monitoring is required since critical dosage decisions are largely based on the INR. PT test systems must give accurate and precise results, and must pass stringent quality control (QC). Accessibility and timeliness of the PT are also crucial.
The Alere INRatio®2 PT/INR Monitoring System is a second-generation portable monitor for evaluating the PT, in INR units, of patients taking warfarin. The test principle is the same as used in the original Alere INRatio® PT/INR Monitoring System (2002), and both systems utilize the same Alere INRatio® Test Strip. The Alere INRatio®2 PT/INR Monitoring System is intended for use by healthcare professionals at the point-of-care (POC) and by patients (or their caregivers) at home on the order of their physician for patient self-testing (PST).
The Alere INRatio®/INRatio®2 PT/INR Monitoring Systems enable a quick, easy and convenient way to confirm that an individual is within their target therapeutic range, or to determine if medication counseling or dose adjustment is needed. With a single drop of finger stick whole blood applied to the test strip, the monitor measures the PT as well as two integrated quality control PT tests at clinical decision points. The INR result is reported once these functional QC and additional electronic QC have passed strict requirements. If QC is ever out of range, the Alere INRatio®2 PT/INR Monitoring System behaves as would a laboratory, and does not report the patient’s INR result, reducing the likelihood of an erroneous result.
The Alere INRatio® Test Strips are manufactured with a human recombinant tissue factor, have an International Sensitivity Index (ISI) close to 1, and are core to both Alere INRatio® and Alere INRatio®2 PT/INR Monitoring Systems. In production for over seven years, hundreds of lots and millions of test strips have delivered accurate, precise and timely INR results worldwide to healthcare professionals and patients at home. For the last five years, the Alere INRatio®2 PT/INR Monitoring System has been the preferred choice by physicians in PT/INR testing at the point of care.*
The purpose of this paper is to evaluate the performance, including precision and accuracy, of the Alere INRatio®2 PT/INR Monitoring System.
METHOD COMPARISONFor OAT patients only, the PT test results are presented in INR units, a calculation adopted in 1983 by the World Health Organization (WHO) to enable comparison of results from PT tests performed using thromboplastins of different sensitivities and from different labs or systems.2 The sensitivity of a thromboplastin is defined by its ISI. Thromboplastins with low ISI values are more sensitive to factor deficiencies. The manufacturer of a commercial thromboplastin assigns an ISI, following WHO guidelines3, to each reagent lot, as well as the mean normal (MN) PT value (determined from non-anticoagulated healthy donors). The following equation calculates the INR based upon the patient’s PT (seconds):
INR = (Patient PT/MN PT)ISI
Each patient’s INR result is calculated automatically by the Alere INRatio®/INRatio®2 PT/INR Monitoring Systems. Precision (Repeatability)
The degree of agreement among a series of measurements of the same quantity is typically reported as coefficient of variation (CV), or how much a result deviates from the mean of all results. A smaller CV is a measure of greater precision. %CV = (SD/mean) x 100% Accuracy
The accuracy of the Alere INRatio®2 PT/INR Monitoring System is evaluated by performing a method comparison. The results of the Alere INRatio®2 PT/INR Monitoring System are compared to the results from a standard laboratory reference. In this study the reference was the widely used laboratory plasma instrument, the Sysmex CA-560 (Kobe, Japan), with Dade Innovin® recombinant human tissue factor reagent (Marburg, Germany). The lab reference blood sample was obtained from the patient using a 3.2% sodium citrate Vacutainer® and processed as plasma according to manufacturer instructions. This reference method had been calibrated to the manual tilt tube method using reference thromboplastin rTF/95.3
Six representative Alere INRatio® test strip lots were evaluated with respect to precision and accuracy. Test strips were tested with capillary finger stick whole blood samples from each patient in duplicate analysis. Over 200 patients on OAT and over 100 nonanticoagulated (normal) volunteer donors were included in the study. The therapeutic donors on OAT were being treated for a variety of disorders, including atrial fibrillation, prior stroke, and coronary artery disease. Patients ranged in age from 27 to 91 years old. Data were analyzed in accordance with current ISO guidelines.4
One-way ANOVAs (analysis of variance) were performed to evaluate whether the INR values from any of the six lots were likely to have come from groups with different means. If a P-value indicated that the null hypothesis (all groups have the same mean) could not be rejected, the data were deemed poolable. Analyses were performed in Matlab® version 184.108.40.2067 (R2009a). Data from all 6 lots were deemed poolable. In addition, while the data are not included here, data from the Alere INRatio®/INRatio®2 PT/INR Monitoring Systems were deemed poolable.
This study reports on the precision and accuracy of the Alere INRatio®2 PT/INR Monitoring System. Previous studies have illustrated that the Alere INRatio®/INRatio®2 PT/INR Monitoring Systems are substantially equivalent in performance.5
RESULTS / DISCUSSION Precision
Six lots of strips were tested on the Alere INRatio®/INRatio®2 PT/INR Monitoring Systems using the same donors with duplicate measures. Precision of the Alere INRatio®2 PT/INR Monitoring System is reported here as having a CV of 5.9% for patients within the therapeutic interval of INR 2.0 to 4.5, and 7.6% for nonanticoagulated (normal) donors. Precision, based on pooled data from the six lots, is summarized in Table 1. TABLE 1: Precision for Alere INRatio®2 PT/INR Monitoring System Accuracy (Method Comparison)
Accuracy is demonstrated by performing a method comparison between the finger stick whole blood test method, Alere INRatio®2 PT/INR Monitoring System and the venous plasma reference method. Accuracy of the system is shown in the tables and depicted in the graphs, below. FIGURE 1: ACCURACY Method comparison, Alere INRatio®2 PT/INR Monitoring System
R=0.966, slope=0.957 +/- 0.0633, intercept=0.0977 +/- 0.157
The correlation of the Alere INRatio®2 PT/INR Monitoring System results (representative lot #3; capillary blood) to plasma results from the Sysmex CA-560 System (Dade Innovin) is shown in Figure 1. Linear regression (n=67) yielded a slope of 0.96 with an intercept of 0.1. The correlation coefficient is 0.97. FIGURE 2: Difference PLOT, Alere INRatio®2 PT/INR Monitoring System Capillary Blood correlation
The difference plot shown in Figure 2 compares the Alere INRatio®2 PT/INR Monitoring System capillary results to Dade Innovin/ Sysmex results. This graph shows that 97% of the results in the therapeutic interval of 2.0 to 4.5 are within the ±30% interval compared to 90% requirement per ISO guideline.
CONCLUSIONPoint-of-care and patient self-testing of the PT test have become widely adopted in the clinical management of patients on chronic warfarin therapy. Compelling evidence supports PST in the context of a comprehensive anticoagulation management plan,6-8 and portable PT monitors are considered enabling technologies that facilitate high-quality management of patients receiving long-term OAT.8 Unique from other POC/PST monitoring tests, such as blood glucose, PT is an activity test based on a series of enzymatic reactions and is not standardized across methods, so there is no “gold” standard for either whole blood or plasma, whether tested in the lab, POC or PST.
Expanded insurance coverage for PST by Medicare and private insurers enables more patients (MHV, Atrial Fibrillation, venous thromboembolism) to access PST.6-7 The unique integrated on-board quality controls on Alere INRatio® Test Strips ensure professional and patient compliance with proper quality assurance of each measurement, reportable at two clinical decision points, and offer QC “lock-out” to significantly reduce the likelihood of erroneous results being reported.
It is equally important that POC/PST systems offer high accuracy and precision. The Alere INRatio®2 PT/INR Monitoring System demonstrates excellent performance when compared to both the Alere INRatio®2 PT/INR Monitoring System and to a plasma-based central laboratory reference system, the Sysmex CA 560 using Dade Innovin. Accuracy of the Alere INRatio®2 PT/INR Monitoring reference system was excellent with an overall correlation of 0.97 to the laboratory reference method for all comparisons. Precision was excellent across the 2.0 to 4.5 INR therapeutic ranges (2.0 – 3.0 and 3.0 –4.5), with 5.9%CV, (mean INR of 3.0) across six strip lots for capillary whole blood samples.
The results of several years of internal and independent studies on Alere INRatio® Test Strips also support the fact that capillary whole blood real-time PT/INR testing with the Alere INRatio®2 PT/INR Monitoring System offer many advantages over venous testing on central lab equipment, which usually involves the treating health care professional basing clinical decisions on a delayed or “stale” INR result rather than a real-time or current result. Timely and accurate availability of INR translates to better patient outcomes and more effective patient and therapy management.8-10 The consistency demonstrated by these results makes the INRatio brands an excellent choice for POC and PST testing, showing strong precision and accuracy.
Acknowledgments: The authors would like to thank the volunteers who have participated in clinical
studies. We would also like to acknowledge the dedication of Alere and in their development and support of Alere INRatio®2 PT/INR Monitoring System products.
REFERENCES1. CHEST 2008; Vol. 133, Number 6 (SUPPL): Antithrombotic and Thrombolytic Therapy: American
College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition): 67S – 970S
2. Loeliger EA, van den Besselaar AMHP, Lewis SM. Reliability and Clinical Impact of the Normalization
of the Prothrombin Times in Oral Anticoagulant Control. Thrombosis and Haemostasis 1985;53:148-154.
3. Guidelines for Thromboplastins and Plasma Used to Control Anticoagulant Therapy.
WHO Technical Report Series #889, Annex 3, World Health Organization (1999).
4. ISO 17593:2007. Clinical laboratory testing and in vitro medical devices - Requirements for in vitro
monitoring systems for self-testing of oral anticoagulant therapy.
5. HemoSense® INRatio®2 system 510(k) K072727 and K021923; Data on file at Alere.
6. Medicare coverage 2008 Centers for Medicare & Medicaid Services (CMS), Pub 100-03 Medicare
National Coverage Determinations, Transmittal 90, Effective March 19, 2008; Implementation Date: August 25, 2008, Change Request 6138
7. National Coverage Decision, # CAG-00087N, Centers for Medicare and Medicaid Services,
8. Supplement to Managed Care. Volume 17, No. 10, Supplement 9, October 2008: Oral
Anticoagulation Patient Self-Testing: Consensus Guidelines For Practical Implementation
9. THINRS Trial: Late Breaking Clinical Trials IV News Conference (Nov. 12, 2008), American Heart
Association Scientific Sessions. Jacobson, AK and D. Matchar. Cooperative Studies Program #481 (Palo Alto Cooperative Studies Program Coordinating Center (CSPCC): The Home INR Study (THINRS): Primary Results.
10. Heneghan, C et al. Self-monitoring of oral anticoagulation: a systematic review and
meta-analysis, The Lancet, 2006; 367:404-11
2011 Alere. All rights reserved. The Alere Logo, Alere and INRatio are trademarks of the Alere group of companies. All trademarks referenced are trademarks of their respective owners. PN: 1000352-01 11/11
Michael Francis Addison Woodruff Bibliography Michael Francis Addison Woodruff—Bibliography (With R. Douglas Wright) The diagnosis, incidence and treatment of avitaminosis A and D in obstructive jaundice. Aust. N.Z. J. Surg., 10 , 135-145. (With R.L.R. Sampimon) Some observations concerning the use of hypnosis as a substitute for anaesthesia. Med. J. Aust., 1 , 393-395. In
BHADRA PHARMA CARE O u r ph a r m a c e u t i c a l m a n u f a c t u r i n g pla n t is eq u i p p e d wit h m o d e r n hig h- sp e e d m a c h i n e s an d inte g r a t e d pa c k a g i n g line s to be co s t effi ci e n t. Ext e n s i v e us e of vis u a l ins p e c t i o n m a c h i n e s , m u l ti- stati o n ta bl e t pr e s s e s , attr a c t i v e pri m a r y pa c k i n g , liq ui d